Glucocorticoid Therapy for COVID-19 Critically Ill Patients With Severe Acute Respiratory Failure

• Status: Completed
• Trial end date: 2020-04-13
• Target enrollment: 0
• Participant gender: All

Summary

In this multi-center, randomized, control study, the investigators will evaluate the efficacy and safety of glucocorticoid in combination with standard care for COVID-19 patents with Severe acute respiratory failure.

• Phase: Phase 2/Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Peking Union Medical College Hospital
• Collaborators: Renmin Hospital of Wuhan University; Zhongda Hospital; Zhongnan Hospital
• Treatments: Glucocorticoids; Methylprednisolone; Methylprednisolone Acetate; Methylprednisolone Hemisuccinate; Prednisolone; Prednisolone acetate; Prednisolone hemisuccinate; Prednisolone phosphate

Criteria

Inclusion Criteria:

• Adult

• PCR confirmed COVID-19 infection

• Symptoms developed more than 7 days

• PaO2/FiO2 < 200 mmHg

• Positive pressure ventilation (non-invasive or invasive) or high flow nasal cannula (HFNC) higher than 45 L/min for less than 48 hours

• Requiring ICU admission

Exclusion Criteria:

• pregnancy;

• patients currently taking corticosteroids (cumulative 400 mg prednisone or equivalent);

• Severe underlying disease, i.e. end stage of malignancy disease or end stage of pulmonary disease;

• Severe adverse events before ICU admission, i.e. cardiac arrest;

• Underlying disease requiring corticosteroids;

• Contraindication for corticosteroids;

• Recruited in other clinical intervention trial